After receiving a random dose of 3 or 5 micrograms of vaccine or placebo (based on two phases of low-dose and high-dose study), the volunteers received the vaccine twice on days 0 and 14 and underwent initial follow-up until day 28 for side effects, humoral and cellular safety. be.Source